Reported about 1 year ago
Pharmally, the biotech leader, reported a consolidated revenue of NT$1.688 billion in May, reaching a new high in nearly 15 months with a 2.77% monthly increase and a 55.76% annual growth. This highlights the renewed growth trajectory of operations after merging with the century-old USL pharmaceutical company, with expectations of continued record-breaking performance this year. The Chairman of Pharmally, Sheng Baoxi, indicated investments in professional technical talents, with a focus on talent development projects in Minnesota, USA. The company is actively strengthening its foothold in the American pharmaceutical market, aiming to enhance local workforce development and become a powerhouse in global pharmaceutical manufacturing and sales.
Source: YAHOO